Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Neisseria Gonorrhoeae Infections Treatment Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Neisseria Gonorrhoeae Infections Treatment Market Status and Forecast (2016-2027)
      • 1.3.2 Global Neisseria Gonorrhoeae Infections Treatment Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Neisseria Gonorrhoeae Infections Treatment Supply by Company

    • 2.1 Global Neisseria Gonorrhoeae Infections Treatment Sales Value by Company
    • 2.2 Neisseria Gonorrhoeae Infections Treatment Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Neisseria Gonorrhoeae Infections Treatment Market Status by Category

    • 3.1 Neisseria Gonorrhoeae Infections Treatment Category Introduction
      • 3.1.1 Cribrostatin-6
      • 3.1.2 Dalbavancin
      • 3.1.3 Debio-1453
      • 3.1.4 Gepotidacin Mesylate
      • 3.1.5 Others
    • 3.2 Global Neisseria Gonorrhoeae Infections Treatment Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Neisseria Gonorrhoeae Infections Treatment Market Status by End User/Segment

    • 4.1 Neisseria Gonorrhoeae Infections Treatment Segment by End User/Segment
      • 4.1.1 Clinic
      • 4.1.2 Hospital
      • 4.1.3 Others
    • 4.2 Global Neisseria Gonorrhoeae Infections Treatment Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Neisseria Gonorrhoeae Infections Treatment Market Status by Region

    • 5.1 Global Neisseria Gonorrhoeae Infections Treatment Market by Region
    • 5.2 North America Neisseria Gonorrhoeae Infections Treatment Market Status
    • 5.3 Europe Neisseria Gonorrhoeae Infections Treatment Market Status
    • 5.4 Asia Pacific Neisseria Gonorrhoeae Infections Treatment Market Status
    • 5.5 Central & South America Neisseria Gonorrhoeae Infections Treatment Market Status
    • 5.6 Middle East & Africa Neisseria Gonorrhoeae Infections Treatment Market Status

    6 North America Neisseria Gonorrhoeae Infections Treatment Market Status

    • 6.1 North America Neisseria Gonorrhoeae Infections Treatment Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Neisseria Gonorrhoeae Infections Treatment Market Status

    • 7.1 Europe Neisseria Gonorrhoeae Infections Treatment Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Neisseria Gonorrhoeae Infections Treatment Market Status

    • 8.1 Asia Pacific Neisseria Gonorrhoeae Infections Treatment Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Neisseria Gonorrhoeae Infections Treatment Market Status

    • 9.1 Central & South America Neisseria Gonorrhoeae Infections Treatment Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Neisseria Gonorrhoeae Infections Treatment Market Status

    • 10.1 Middle East & Africa Neisseria Gonorrhoeae Infections Treatment Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Neisseria Gonorrhoeae Infections Treatment Market Forecast by Category and by End User/Segment

    • 12.1 Global Neisseria Gonorrhoeae Infections Treatment Sales Value Forecast (2022-2027)
    • 12.2 Global Neisseria Gonorrhoeae Infections Treatment Forecast by Category
    • 12.3 Global Neisseria Gonorrhoeae Infections Treatment Forecast by End User/Segment

    13 Global Neisseria Gonorrhoeae Infections Treatment Market Forecast by Region/Country

    • 13.1 Global Neisseria Gonorrhoeae Infections Treatment Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Sumitomo Dainippon Pharma Co., Ltd.
      • 14.1.1 Company Information
      • 14.1.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.1.3 Sumitomo Dainippon Pharma Co., Ltd. Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Sarepta Therapeutics, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.2.3 Sarepta Therapeutics, Inc. Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Redx Pharma Plc
      • 14.3.1 Company Information
      • 14.3.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.3.3 Redx Pharma Plc Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Recce Pty Ltd
      • 14.4.1 Company Information
      • 14.4.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.4.3 Recce Pty Ltd Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Paratek Pharmaceuticals, Inc.
      • 14.5.1 Company Information
      • 14.5.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.5.3 Paratek Pharmaceuticals, Inc. Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Merck & Co., Inc.
      • 14.6.1 Company Information
      • 14.6.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.6.3 Merck & Co., Inc. Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 GlaxoSmithKline Plc
      • 14.7.1 Company Information
      • 14.7.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.7.3 GlaxoSmithKline Plc Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 F. Hoffmann-La Roche Ltd.
      • 14.8.1 Company Information
      • 14.8.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.8.3 F. Hoffmann-La Roche Ltd. Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Debiopharm International SA
      • 14.9.1 Company Information
      • 14.9.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.9.3 Debiopharm International SA Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Biolytics Pharma
      • 14.10.1 Company Information
      • 14.10.2 Neisseria Gonorrhoeae Infections Treatment Product Introduction
      • 14.10.3 Biolytics Pharma Neisseria Gonorrhoeae Infections Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 BioDiem Ltd
    • 14.12 Allergan Plc

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Neisseria Gonorrhoeae Infections Treatment market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Neisseria Gonorrhoeae Infections Treatment market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Cribrostatin-6
      Dalbavancin
      Debio-1453
      Gepotidacin Mesylate
      Others

      Segmented by End User/Segment
      Clinic
      Hospital
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Sumitomo Dainippon Pharma Co., Ltd.
      Sarepta Therapeutics, Inc.
      Redx Pharma Plc
      Recce Pty Ltd
      Paratek Pharmaceuticals, Inc.
      Merck & Co., Inc.
      GlaxoSmithKline Plc
      F. Hoffmann-La Roche Ltd.
      Debiopharm International SA
      Biolytics Pharma
      BioDiem Ltd
      Allergan Plc
      Buy now